Medical/Pharmaceuticals

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

SHANGHAI, Dec. 26, 2023 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney ...

2023-12-26 17:26 2911

PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development

NANJING, China, Dec. 25, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has announced the successful attainment of Energy Management System Certification...

2023-12-26 11:00 3600

FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy

NANJING, China, Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. However, the transition from basic research to clinical commercialization presents formidable challenge...

2023-12-25 10:15 3115

APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...

2023-12-24 17:53 4100

GenSci Launches Global Innovation Hub in Shanghai

The Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ -- Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), h...

2023-12-23 15:41 4146

TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma

NANJING, China and GAITHURSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420), ...

2023-12-21 21:45 2229

BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

WUXI, China, Dec. 20, 2023 /PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) inCh...

2023-12-21 08:26 2336

/DISREGARD RELEASE: YS Biopharma/

We are advised by YS Biopharma Co., Ltd. (NASDAQ:YS) that journalists and other readers should disregard the news release, "YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting onDecember 28, 2023", issued on December 20, 2023 by YS Biopharma over PR Newswire, as the release contained err...

2023-12-21 05:15 3809

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors

HANGZHOU, China, Dec. 20, 2023 /PRNewswire/ -- Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital inChina.  "A single center, single-arm, dose-escalation, exploratory clinical trial to examine t...

2023-12-21 01:00 2691

Genevoyager Unveils Gene Therapy CDMO Facility in Milestone Move

PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider of one-stop CRO/CDMO services for gene therapy products, proudly announces the official opening of its Contract Development and Manufacturing Organization (CDMO) facility. This significant ...

2023-12-20 23:10 2324

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum

ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...

2023-12-20 20:00 2656

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit®  linker-payload pl...

2023-12-20 09:00 3630

Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case

SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discovery and development, today announced that it has been included in a recent Gartner report, entitled,Emerging Tech: Tech Innovators fo...

2023-12-19 22:00 3237

New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA

SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injec...

2023-12-19 20:00 2429

Tianjin's Youthful Energy Sparks Citywide Revival

TIANJIN, China, Dec. 19, 2023 /PRNewswire/ -- A report from China Daily: Tianjin, a city in North China, is undergoing a dynamic transformation driven by its vibrant young people. China Daily Potside Chats hosts, Nathan and Stephanie, recently explored the city's cutting-edge developments led by ...

2023-12-19 15:44 2931

Biorithm Secures $3.5 Million in Series A Funding to Advance Maternal Care Worldwide

New funds to fortify US market entry and growth strategy, as well as advance breakthrough research CAMBRIDGE, Mass., Dec. 18, 2023 /PRNewswire/ -- Biorithm, a global women's health medtech, has closed$3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital. With a ...

2023-12-18 22:00 2463

Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome

Highlights:  * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures   * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...

2023-12-18 19:00 2193

NUS researchers develop an innovative and flexible method to study immune cell capabilities

This simple and efficient method can directly identify and sort immune cells involved in cell-mediated cytotoxicity SINGAPORE, Dec. 17, 2023 /PRNewswire/ -- Our body's immune system is a complex network of organs, cells, and proteins that work in synchrony to protect our bodies against infection...

2023-12-18 14:47 2333

GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)

YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...

2023-12-18 09:49 2766

GeneQuantum and BioMap establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics

SUZHOU, China, Dec. 17, 2023 /PRNewswire/ -- Recently, GeneQuantum Healthcare (GQ), a global leader in ADC new drug development focused on innovative bioconjugation technologies, and BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, announced that the...

2023-12-18 09:43 2462
1 ... 153154155156157158159 ... 264